Video

Aerie COO: Expanding innovation of glaucoma therapeutics

Author(s):

OT Staff Reports
Conferences|GLAUCOMA 360

Tom Mitro, president, COO of Aerie Pharmaceuticals, discusses the key highlights from an industry panel discussion titled "Innovate without borders," held during the Glaucoma 360 New Horizons Forum, including the company's role in expanding into the global glaucoma therapeutics market.

See more Glaucoma 360 coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
Related Content
(Image credit: AdobeStock/RFBSIP) The impact of preservatives on the ocular surface in patients with ocular hypertension or glaucoma
June 4th 2025

The impact of preservatives on the ocular surface in patients with ocular hypertension or glaucoma

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Q&A: Rachel Downes, MD, provides highlights from the GATHER1 and GATHER2 clinical trials for GA
June 2nd 2025

Q&A: Rachel Downes, MD, provides highlights from the GATHER1 and GATHER2 clinical trials for GA

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Q&A: Sharon Fekrat, MD, FACS, FASRS, on the value of scientific meetings and collaboration
May 31st 2025

Q&A: Sharon Fekrat, MD, FACS, FASRS, on the value of scientific meetings and collaboration

Q&A: Dilraj S. Grewal, MD, FASRS, on therapeutics for non-infectious uveitis
May 30th 2025

Q&A: Dilraj S. Grewal, MD, FASRS, on therapeutics for non-infectious uveitis

© 2025 MJH Life Sciences

All rights reserved.